BFRA Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 01:00):

Stats
Tagesvolumen	4 951.00
Durchschnittsvolumen	30 523.00
Marktkapitalisierung	0.00
EPS	$0 ( 2022-04-11 )
Last Dividend	$0.104 ( 2021-02-24 )
Next Dividend	$0 ( N/A )
P/E	-4.35
ATR14	$0.324 (12.13%)

Volumen Korrelation

Lang: 0.02 (neutral)

Kurz: -0.25 (neutral)

Signal:(42.752) Neutral

Biofrontera AG Korrelation

10 Am meisten positiv korreliert
SOHU	0.914
CHB	0.904
NWL	0.904
CSSEP	0.903
TSRI	0.902
AOUT	0.902
HPK	0.9
BMRA	0.897
MODV	0.897
OGI	0.895

10 Am meisten negativ korreliert
APXI	-0.914
WINV	-0.908
FRSG	-0.907
KAII	-0.906
ZEUS	-0.906
MLAI	-0.905
MATW	-0.904
ALSA	-0.904
MSAC	-0.903
PTOC	-0.903

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Biofrontera AG Korrelation - Währung/Rohstoff

-0.78
( moderate negative )

-0.69
( moderate negative )

0.77
( moderate )

-0.78
( moderate negative )

-0.26
( neutral )

0.47
( neutral )

Biofrontera AG Finanzdaten

Annual	2020
Umsatz:	$30.35M
Bruttogewinn:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2020
Umsatz:	$30.35M
Bruttogewinn:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2019
Umsatz:	$31.27M
Bruttogewinn:	$26.39M (84.41 %)
EPS:	$-0.312

FY	2018
Umsatz:	$21.11M
Bruttogewinn:	$16.66M (78.91 %)
EPS:	$-0.389

Financial Reports:

No articles found.

Biofrontera AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Biofrontera AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0221	2020-03-18
Last Dividend	$0.104	2021-02-24
Next Dividend	$0	N/A
Payout Date	2021-03-04
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.19%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-01-06)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	$0.0221	0.22%
2021	$0.104	1.30%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.429	1.500	-8.58	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.231	1.200	-7.70	-9.24	[0 - 0.3]
returnOnEquityTTM	-1.503	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.48	0.800	0.0937	0.0750	[0.8 - 2.5]
cashRatioTTM	1.997	1.500	0.0174	0.0262	[0.2 - 2]
debtRatioTTM	0.423	-1.500	2.94	-4.42	[0 - 0.6]
interestCoverageTTM	-2.47	1.000	-2.03	-2.03	[3 - 30]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0651	-0.130	[0 - 20]
debtEquityRatioTTM	3.24	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.883	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.251	1.000	-7.02	-7.02	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.119	1.000	-1.774	-1.774	[0.2 - 2]
assetTurnoverTTM	0.538	0.800	9.75	7.80	[0.5 - 2]
Total Score				-0.244

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.33	1.000	-0.640	0	[1 - 100]
returnOnEquityTTM	-1.503	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0434	-0.130	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.28	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0939	1.000	-4.85	0	[0.1 - 0.5]
Total Score				-2.56

Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.